Chemotherapeutic candidate inducing immunological death of human tumor cell lines.
Chemotherapeutic candidate inducing immunological death of human tumor cell lines.
复制标题
DOI：
10.4110/in.2012.12.2.66
复制
发表时间：
2012-04-01
期刊：
影响因子：
6
通讯作者：
Lee, Hyunah
中科院分区：
文献类型：
--
作者：
Oh, Su-Jin;Ryu, Chung-Kyu;Lee, Hyunah
筛选EY-6对人肿瘤细胞系的免疫死亡诱导作用。 EY-6以剂量依赖性方式处理人结肠癌（HCT15、HCT116）、胃癌（MKN74、SNU668）和骨髓瘤（KMS20、KMS26、KMS34）细胞。 CRT 表达是免疫死亡的典型标志，在 EY-6 处理的结直肠癌细胞和胃癌细胞中增加。有趣的是，对骨髓瘤细胞系的影响很复杂，显示出细胞系依赖性的差异调节。 EY-6处理的肿瘤细胞的细胞因子分泌具有剂量和细胞依赖性。处理细胞中IFN-γ和IL-12的分泌增加（未处理对照的200%至超过1000%），但HCT116、SNU668和KMS26细胞除外，EY-6使它们的分泌减少。数据表明 EY-6 作为一种新型免疫化疗药物诱导肿瘤特异性细胞死亡的潜力。计划进一步研究以证实 EY-6 的功效，包括体内研究。
The immunological death induction by EY-6 on the human tumor cell lines was screened. Human colon carcinoma (HCT15, HCT116), gastric carcinoma (MKN74, SNU668), and myeloma (KMS20, KMS26, KMS34) cells were died by EY-6 treatment with dose-dependent manner. CRT expression, a typical marker for the immunological death, was increased on the EY-6-treated colorectal and gastric cancer cells. Interestingly, the effects on the myeloma cell lines were complicated showing cell line dependent differential modulation. Cytokine secretion from the EY-6 treated tumor cells were dose and cell-dependent. IFN-gamma and IL-12 secretion was increased in the treated cells (200% to over 1000% of non-treated control), except HCT116, SNU668 and KMS26 cells which their secretion was declined by EY-6. Data suggest the potential of EY-6 as a new type of immuno-chemotherapeutics inducing tumor-specific cell death. Further studies are planned to confirm the efficacy of EY-6 including in vivo study.